CUSIP
No. 74838L304
|
Page 2
of 10 Pages
|
1
|
NAME
OF REPORTING PERSON
SS.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Ted
Karkus
|
||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
Instructions)
(a)
¨
(b)
x
|
||
3
|
SEC
USE ONLY
|
||
4
|
SOURCE
OF FUNDS (see Instructions)
PF
|
||
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)
¨
|
||
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
||
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
620,850
|
|
8
|
SHARED
VOTING POWER
0
|
||
9
|
SOLE
DISPOSITIVE POWER
620,850
|
||
10
|
SHARED
DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
620,850
|
||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see
Instructions)
¨
|
||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.8%
|
||
14
|
TYPE
OF REPORTING PERSON (see Instructions)
IN
|
CUSIP
No. 74838L304
|
Page 3
of 10 Pages
|
1
|
NAME
OF REPORTING PERSON
SS.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mark
Burnett
|
||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
Instructions)
(a)
¨
(b)
x
|
||
3
|
SEC
USE ONLY
|
||
4
|
SOURCE
OF FUNDS (see Instructions)
PF
|
||
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)
¨
|
||
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
||
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
151,473
|
|
8
|
SHARED
VOTING POWER
0
|
||
9
|
SOLE
DISPOSITIVE POWER
151,473
|
||
10
|
SHARED
DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
151,473
|
||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see
Instructions)
¨
|
||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.2%
|
||
14
|
TYPE
OF REPORTING PERSON (see Instructions)
IN
|
CUSIP
No. 74838L304
|
Page 4
of 10 Pages
|
1
|
NAME
OF REPORTING PERSON
SS.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
John
DeShazo
|
||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
Instructions)
(a)
¨
(b)
x
|
||
3
|
SEC
USE ONLY
|
||
4
|
SOURCE
OF FUNDS (see Instructions)
PF
|
||
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)
¨
|
||
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
||
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
277,000
|
|
8
|
SHARED
VOTING POWER
0
|
||
9
|
SOLE
DISPOSITIVE POWER
277,000
|
||
10
|
SHARED
DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
277,000
|
||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see
Instructions)
¨
|
||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.1%
|
||
14
|
TYPE
OF REPORTING PERSON (see Instructions)
IN
|
CUSIP
No. 74838L304
|
Page 5
of 10 Pages
|
1
|
NAME
OF REPORTING PERSON
SS.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Louis
Gleckel, MD
|
||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
Instructions)
(a)
¨
(b)
x
|
||
3
|
SEC
USE ONLY
|
||
4
|
SOURCE
OF FUNDS (see Instructions)
PF
|
||
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)
¨
|
||
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
||
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
20,000
|
|
8
|
SHARED
VOTING POWER
0
|
||
9
|
SOLE
DISPOSITIVE POWER
20,000
|
||
10
|
SHARED
DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
20,000
|
||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see
Instructions)
¨
|
||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.1%
|
||
14
|
TYPE
OF REPORTING PERSON (see Instructions)
IN
|
CUSIP
No. 74838L304
|
Page 6
of 10 Pages
|
1
|
NAME
OF REPORTING PERSON
SS.
OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Mark
Leventhal
|
||
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see
Instructions)
(a)
¨
(b)
x
|
||
3
|
SEC
USE ONLY
|
||
4
|
SOURCE
OF FUNDS (see Instructions)
PF
|
||
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e)
¨
|
||
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
USA
|
||
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
|
7
|
SOLE
VOTING POWER
240,000
|
|
8
|
SHARED
VOTING POWER
0
|
||
9
|
SOLE
DISPOSITIVE POWER
240,000
|
||
10
|
SHARED
DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
240,000
|
||
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see
Instructions)
¨
|
||
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.9%
|
||
14
|
TYPE
OF REPORTING PERSON (see Instructions)
IN
|
CUSIP
No. 74838L304
|
Page 7
of 10 Pages
|
CUSIP
No. 74838L304
|
Page 8
of 10 Pages
|
CUSIP
No. 74838L304
|
Page 9
of 10 Pages
|
Reporting Person
|
Trade Date
|
Shares Purchased (Sold)
|
Price Per Share ($)
|
|||
Mark
Burnett
|
2/9/09
|
1,000
|
4.59
|
|||
Mark
Burnett
|
2/13/09
|
7,175
|
4.59
|
|||
Mark
Burnett
|
2/27/09
|
1,000
|
4.24
|
|||
Mark
Burnett
|
3/2/09
|
2,500
|
4.17
|
|||
Mark
Burnett
|
3/3/09
|
5,000
|
4.24
|
|||
Mark
Burnett
|
3/4/09
|
400
|
4.08
|
|||
Mark
Burnett
|
3/4/09
|
1,200
|
4.09
|
|||
Mark
Burnett
|
3/5/09
|
4,900
|
3.99
|
|||
Mark
Burnett
|
3/6/09
|
2,500
|
4.07
|
|||
Mark
Burnett
|
3/10/09
|
2,500
|
4.14
|
|||
Mark
Burnett
|
3/11/09
|
2,000
|
4.01
|
|||
Mark
Burnett
|
3/12/09
|
3,345
|
4.24
|
|||
Mark
Burnett
|
3/16/09
|
100
|
4.16
|
|||
Mark
Burnett
|
3/19/09
|
1,000
|
4.42
|
|||
Mark
Burnett
|
3/23/09
|
2,500
|
4.52
|
|||
Mark
Burnett
|
3/24/09
|
1,861
|
4.53
|
|||
Mark
Leventhal
|
02/06/09
|
350
|
4.51
|
|||
Mark
Leventhal
|
02/10/09
|
1800
|
4.45
|
|||
Mark
Leventhal
|
02/11/09
|
1400
|
4.51
|
|||
Mark
Leventhal
|
02/19/09
|
1400
|
4.15
|
|||
Mark
Leventhal
|
02/25/09
|
50
|
4.35
|
CUSIP
No. 74838L304
|
Page 10
of 10 Pages
|
April
7, 2009
|
/s/ Ted Karkus
|
|
By: Ted
Karkus
|
||
Dated:
|
April
7, 2009
|
/s/ Mark Burnett
|
By: Mark
Burnett
|
||
Dated:
|
April
7, 2009
|
/s/ John DeShazo
|
By: John
DeShazo
|
||
Dated:
|
April
7, 2009
|
/s/ Louis Gleckel, MD.
|
By: Louis
Gleckel, M.D.
|
||
Dated:
|
April
7, 2009
|
/s/ Mark Leventhal
|
By: Mark
Leventhal
|